CoChat
Sign Up
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis

Ustun, Celalettin, DeRemer, David L., Akin, Cem·2011·Leukemia Research
DOI 10.1016/j.leukres.2011.05.006
Open this paper in CoChat — free account

Abstract

Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KIT(D816V)). A small subset of SM patients with KIT(D816V) mutation require cytoreductive therapy. In these patients, tyrosine kinase inhibitors (TKIs) have been actively investigated over the last decade because of codon 816 KIT mutations causing constitutive activation of tyrosine kinase activity of the molecule. The main question has been whether the success story with imatinib in chronic myeloid leukemia (CML), another disease associated with a constitutively active tyrosine kinase, could be mimicked in mastocytosis. However, the results from various TKIs in SM with KIT(D816V) mutation have been disappointing to date. Only a few of the TKIs sufficiently block KIT(D816V) activity and have shown promising clinical results. The data from these studies indicate that, apart from KIT(D816V), other kinase targets and target pathways may play a role in disease evolution and progression, especially in patients with SM with an associated clonal hematological non-mast cell lineage disease (SM-AHNMD). Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17. This review will focus on the KIT receptor, KIT mutations, and the effec…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.leukres.2011.05.006

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 144

  1. Valent, 2001, Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leuk Res, 25, 603, 10.1016/S0145-2126(01)00038-8 · DOI
  2. Lim, 2009, Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors, Blood, 113, 5727, 10.1182/blood-2009-02-205237 · DOI
  3. Escribano, 2009, Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients, J Allergy Clin Immunol, 124, 514, 10.1016/j.jaci.2009.05.003 · DOI
  4. Valent, 2006, How I treat patients with advanced systemic mastocytosis. Blood 2010, 6, Robyn J, Metcalfe DD. Systemic mastocytosis, Adv Immunol, 89, 169
  5. Robyn, 2006, Systemic mastocytosis, Adv Immunol, 89, 169, 10.1016/S0065-2776(05)89005-4 · DOI
  6. Hennessy, 2004, Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience, Am J Hematol, 77, 209, 10.1002/ajh.20211 · DOI
  7. Bains, 2010, Current approaches to the diagnosis and treatment of systemic mastocytosis, Ann Allergy Asthma Immunol, 104, 1, 10.1016/j.anai.2009.11.006 · DOI
  8. Bunimovich, 2009, Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment, Cutis, 83, 29
  9. Pardanani, 2010, Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature, Curr Opin Hematol, 17, 125, 10.1097/MOH.0b013e3283366c59 · DOI
  10. Horny, 2009, Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells, Am J Clin Pathol, 132, 438, 10.1309/AJCPPXHMN5CJOXHZ · DOI
  11. Valent, 2008, Systemic mastocytosis, Cancer Treat Res, 142, 399
  12. Horny, 2007, Mastocytosis: state of the art, Pathobiology, 74, 121, 10.1159/000101711 · DOI
  13. Pardanani, 2006, Pathogenesis, clinical features, and treatment advances in mastocytosis, Best Pract Res Clin Haematol, 19, 595, 10.1016/j.beha.2005.07.010 · DOI
  14. Valent, 2005, Mastocytosis: pathology, genetics, and current options for therapy, Leuk Lymphoma, 46, 35, 10.1080/10428190400010775 · DOI
  15. Akin, 2005, Clonality and molecular pathogenesis of mastocytosis, Acta Haematol, 114, 61, 10.1159/000085563 · DOI
  16. Kitamura, 2004, Kit as a human oncogenic tyrosine kinase, Cell Mol Life Sci, 61, 2924, 10.1007/s00018-004-4273-y · DOI
  17. Boissan, 2000, c-Kit and c-kit mutations in mastocytosis and other hematological diseases, J Leukoc Biol, 67, 135, 10.1002/jlb.67.2.135 · DOI
  18. Ronnstrand, 2004, Signal transduction via the stem cell factor receptor/c-kit, Cell Mol Life Sci, 61, 2535, 10.1007/s00018-004-4189-6 · DOI
  19. Fukuda, 1995, Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia, J Pathol, 177, 139, 10.1002/path.1711770207 · DOI
  20. Miettinen, 2005, KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation, Appl Immunohistochem Mol Morphol, 13, 205, 10.1097/01.pai.0000173054.83414.22 · DOI
  21. Dym, 1995, Expression of c-kit receptor and its autophosphorylation in immature rat type A spermatogonia, Biol Reprod, 52, 8, 10.1095/biolreprod52.1.8 · DOI
  22. Blume-Jensen, 1998, The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136, Curr Biol, 8, 779, 10.1016/S0960-9822(98)70302-1 · DOI
  23. Pawson, 2004, Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems, Cell, 116, 191, 10.1016/S0092-8674(03)01077-8 · DOI
  24. Mol, 2003, Structure of a c-kit product complex reveals the basis for kinase transactivation, J Biol Chem, 278, 31461, 10.1074/jbc.C300186200 · DOI
  25. Masson, 2009, Oncogenic signaling from the hematopoietic growth factor receptors c-kit and Flt3, Cell Signal, 21, 1717, 10.1016/j.cellsig.2009.06.002 · DOI
  26. Yarden, 1987, Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand, EMBO J, 6, 3341, 10.1002/j.1460-2075.1987.tb02655.x · DOI
  27. Qiu, 1988, Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family—oncogenic activation of v-kit involves deletion of extracellular domain and C terminus, EMBO J, 7, 1003, 10.1002/j.1460-2075.1988.tb02907.x · DOI
  28. Zakut, 1993, KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells, Oncogene, 8, 2221
  29. Lemmon, 1997, Kit receptor dimerization is driven by bivalent binding of stem cell factor, J Biol Chem, 272, 6311, 10.1074/jbc.272.10.6311 · DOI
  30. Linnekin, 1999, Early signaling pathways activated by c-Kit in hematopoietic cells, Int J Biochem Cell Biol, 31, 1053, 10.1016/S1357-2725(99)00078-3 · DOI
  31. Karin, 1992, Signal transduction from cell surface to nucleus in development and disease, FASEB J, 6, 2581, 10.1096/fasebj.6.8.1317309 · DOI
  32. Irani, 1992, Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells, Blood, 80, 3009, 10.1182/blood.V80.12.3009.3009 · DOI
  33. Valent, 1992, Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture, Blood, 80, 2237, 10.1182/blood.V80.9.2237.2237 · DOI · Paper page
  34. Kirshenbaum, 1992, Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells, J Immunol, 148, 772, 10.4049/jimmunol.148.3.772 · DOI
  35. Mitsui, 1993, Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand, Proc Natl Acad Sci USA, 90, 735, 10.1073/pnas.90.2.735 · DOI
  36. Shelburne, 2003, Stat5 expression is critical for mast cell development and survival, Blood, 102, 1290, 10.1182/blood-2002-11-3490 · DOI
  37. Iemura, 1994, The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis, Am J Pathol, 144, 321
  38. Lohning, 1998, T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function, Proc Natl Acad Sci USA, 95, 6930, 10.1073/pnas.95.12.6930 · DOI
  39. Hayakawa, 2007, Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation, J Biol Chem, 282, 26369, 10.1074/jbc.M704916200 · DOI
  40. Kuehn, 2007, G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation, Immunol Lett, 113, 59, 10.1016/j.imlet.2007.08.007 · DOI
  41. Drube, 2010, The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells, Blood, 115, 3899, 10.1182/blood-2009-10-247411 · DOI
  42. Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 · DOI
  43. Naeem, 2002, Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis, Hum Pathol, 33, 1182, 10.1053/hupa.2002.129199 · DOI
  44. Bellone, 1997, Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1, J Cell Physiol, 172, 1, 10.1002/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO;2-S · DOI
  45. Nakata, 1995, c-kit point mutation of extracellular domain in patients with myeloproliferative disorders, Br J Haematol, 91, 661, 10.1111/j.1365-2141.1995.tb05364.x · DOI
  46. Cohen, 1994, Expression of stem cell factor and c-kit in human neuroblastoma, The Children's Cancer Group, Blood, 84, 3465, 10.1182/blood.V84.10.3465.3465 · DOI
  47. Natali, 1992, Breast cancer is associated with loss of the c-kit oncogene product, Int J Cancer, 52, 713, 10.1002/ijc.2910520508 · DOI
  48. Patnaik, 2007, Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders, Curr Cancer Drug Targets, 7, 492, 10.2174/156800907781386614 · DOI
  49. Piao, 1996, A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells, Blood, 87, 3117, 10.1182/blood.V87.8.3117.bloodjournal8783117 · DOI · Paper page
  50. Tsujimura, 1994, Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation, Blood, 83, 2619, 10.1182/blood.V83.9.2619.2619 · DOI · Paper page
  51. Furitsu, 1993, Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product, J Clin Invest, 92, 1736, 10.1172/JCI116761 · DOI
  52. Kitayama, 1995, Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines, Blood, 85, 790, 10.1182/blood.V85.3.790.bloodjournal853790 · DOI · Paper page
  53. Tsujimura, 1995, Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3, Int Arch Allergy Immunol, 106, 377, 10.1159/000236870 · DOI
  54. Hashimoto, 1996, Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line, Am J Pathol, 148, 189
  55. Nagata, 1995, Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder, Proc Natl Acad Sci USA, 92, 10560, 10.1073/pnas.92.23.10560 · DOI
  56. Longley, 1996, Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm, Nat Genet, 12, 312, 10.1038/ng0396-312 · DOI
  57. Garcia-Montero, 2006, KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients, Blood, 108, 2366, 10.1182/blood-2006-04-015545 · DOI
  58. Pignon, 1997, A new c-kit mutation in a case of aggressive mast cell disease, Br J Haematol, 96, 374, 10.1046/j.1365-2141.1997.d01-2042.x · DOI
  59. Longley, 1999, Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis, Proc Natl Acad Sci USA, 96, 1609, 10.1073/pnas.96.4.1609 · DOI
  60. Pullarkat, 2003, Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations, Am J Hematol, 73, 12, 10.1002/ajh.10322 · DOI
  61. Sotlar, 2003, One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes, Am J Pathol, 162, 737, 10.1016/S0002-9440(10)63870-9 · DOI
  62. Nakagomi, 2007, Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation, Lab Invest, 87, 365, 10.1038/labinvest.3700524 · DOI
  63. Buttner, 1998, Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior, J Invest Dermatol, 111, 1227, 10.1046/j.1523-1747.1998.00414.x · DOI
  64. Akin, 2004, A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib, Blood, 103, 3222, 10.1182/blood-2003-11-3816 · DOI · Paper page
  65. Ozer, 2008, The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells, Leuk Lymp, 49, 1567, 10.1080/10428190802140865 · DOI
  66. Tang, 2004, A germline mutation in KIT in familial diffuse cutaneous mastocytosis, J Med Genet, 41, e88, 10.1136/jmg.2003.015156 · DOI · Paper page
  67. Zhang, 2006, A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy, Leuk Res, 30, 373, 10.1016/j.leukres.2005.08.015 · DOI · Paper page
  68. Hartmann, 2005, Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis, Gastroenterology, 129, 1042, 10.1053/j.gastro.2005.06.060 · DOI · Paper page
  69. Hoffmann, 2008, Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation, Blood, 112, 1655, 10.1182/blood-2008-03-147785 · DOI
  70. Yanagihori, 2005, c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation, J Mol Diagn, 7, 252, 10.1016/S1525-1578(10)60552-1 · DOI
  71. Verzijl, 2007, C-kit Asp-816-Val mutation analysis in patients with mastocytosis, Dermatology, 214, 15, 10.1159/000096907 · DOI
  72. Teodosio, 2010, Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes, J Allergy Clin Immunol, 125, 719, 10.1016/j.jaci.2009.10.020 · DOI
  73. Yavuz, 2002, Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene, Blood, 100, 661, 10.1182/blood-2002-01-0203 · DOI
  74. Akin, 2000, Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis, Exp Hematol, 28, 140, 10.1016/S0301-472X(99)00145-9 · DOI
  75. Baumgartner, 2009, Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V, Am J Pathol, 175, 2416, 10.2353/ajpath.2009.080953 · DOI
  76. Shelburne, 2003, Stat5 expression is critical for mast cell development and survival, Blood, 102, 1290, 10.1182/blood-2002-11-3490 · DOI
  77. Shelburne, 2002, Stat5: an essential regulator of mast cell biology, Mol Immunol, 38, 1187, 10.1016/S0161-5890(02)00061-5 · DOI
  78. Harir, 2008, Oncogenic kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade, Blood, 112, 2463, 10.1182/blood-2007-09-115477 · DOI
  79. Ning, 2001, Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells, Blood, 97, 3559, 10.1182/blood.V97.11.3559 · DOI
  80. Chaix, 2011, Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells, J Biol Chem, 286, 5956, 10.1074/jbc.M110.182642 · DOI
  81. Mekori, 2001, Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL, J Clin Immunol, 21, 171, 10.1023/A:1011083031272 · DOI
  82. Cervero, 1999, Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia, Am J Hematol, 60, 191, 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y · DOI
  83. Aichberger, 2009, Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs, Blood, 114, 5342, 10.1182/blood-2008-08-175190 · DOI
  84. Moller, 2005, Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim, Blood, 106, 1330, 10.1182/blood-2004-12-4792 · DOI
  85. Chian, 2001, Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant, Blood, 98, 1365, 10.1182/blood.V98.5.1365 · DOI
  86. Blume-Jensen, 1993, Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C, EMBO J, 12, 4199, 10.1002/j.1460-2075.1993.tb06104.x · DOI
  87. Blume-Jensen, 1995, Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells, J Biol Chem, 270, 14192, 10.1074/jbc.270.23.14192 · DOI
  88. Mauro, 2009, Management of drug toxicities in chronic myeloid leukaemia, Best Pract Res Clin Haematol, 22, 409, 10.1016/j.beha.2009.06.001 · DOI
  89. Chen, 2003, Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors, Int J Cancer, 105, 130, 10.1002/ijc.11025 · DOI
  90. Akin, 2003, Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit, Exp Hematol, 31, 686, 10.1016/S0301-472X(03)00112-7 · DOI
  91. Ma, 2002, The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations, Blood, 99, 1741, 10.1182/blood.V99.5.1741 · DOI
  92. Frost, 2002, Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant, Mol Cancer Ther, 1, 1115
  93. Zermati, 2003, Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms, Oncogene, 22, 660, 10.1038/sj.onc.1206120 · DOI
  94. Longley, 2000, New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors, Hematol Oncol Clin North Am, 14, 689, 10.1016/S0889-8588(05)70302-6 · DOI
  95. Vega-Ruiz, 2009, Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis, Leuk Res, 33, 1481, 10.1016/j.leukres.2008.12.020 · DOI
  96. Pagano, 2008, Advanced mast cell disease: an Italian hematological multicenter experience, Int J Hematol, 88, 483, 10.1007/s12185-008-0166-4 · DOI
  97. Pardanani, 2003, Imatinib for systemic mast-cell disease, Lancet, 362, 535, 10.1016/S0140-6736(03)14115-3 · DOI
  98. Lim, 2009, Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine, Am J Hematol, 84, 790, 10.1002/ajh.21561 · DOI
  99. Droogendijk, 2006, Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial, Cancer, 107, 345, 10.1002/cncr.21996 · DOI
  100. Heinrich, 2008, Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases, Clin Cancer Res, 14, 2717, 10.1158/1078-0432.CCR-07-4575 · DOI
  101. Gotlib, 2004, The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management, Blood, 103, 2879, 10.1182/blood-2003-06-1824 · DOI
  102. Klion, 2003, Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness, Blood, 101, 4660, 10.1182/blood-2003-01-0006 · DOI
  103. Pardanani, 2003, CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy, Blood, 102, 3093, 10.1182/blood-2003-05-1627 · DOI
  104. Yamada, 2010, FIP1L1/PDGFR alpha-associated systemic mastocytosis, Int Arch Allergy Immunol, 152, 101, 10.1159/000312134 · DOI
  105. Lahortiga, 2008, Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion, Haematologica, 93, 49, 10.3324/haematol.11836 · DOI
  106. Pardanani, 2007, Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease, Cancer J, 13, 384, 10.1097/PPO.0b013e31815a9618 · DOI
  107. Florian, 2006, Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib, Leuk Res, 30, 1201, 10.1016/j.leukres.2005.11.014 · DOI
  108. Schittenhelm, 2006, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies, Cancer Res, 66, 473, 10.1158/0008-5472.CAN-05-2050 · DOI
  109. Fabarius, 2008, Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib, Haematologica, 93, 1145, 10.3324/haematol.12793 · DOI
  110. Shah, 2006, Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis, Blood, 108, 286, 10.1182/blood-2005-10-3969 · DOI
  111. Gleixner, 2007, Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT, Haematologica, 92, 1451, 10.3324/haematol.11339 · DOI
  112. Aichberger, 2008, Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis, Eur J Clin Invest, 38, 869, 10.1111/j.1365-2362.2008.02036.x · DOI
  113. Gleixner, 2006, PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects, Blood, 107, 752, 10.1182/blood-2005-07-3022 · DOI
  114. Verstovsek, 2008, Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis, Clin Cancer Res, 14, 3906, 10.1158/1078-0432.CCR-08-0366 · DOI
  115. Purtill, 2008, Dasatinib therapy for systemic mastocytosis: four cases, Eur J Haematol, 80, 456, 10.1111/j.1600-0609.2008.01048.x · DOI
  116. Benz, 2007, Systemic mastocytosis with c-KITD816V mutation treated with dasatinib, Blood, 110
  117. Ustun, 2009, Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V, Leuk Res, 33, 735, 10.1016/j.leukres.2008.09.027 · DOI
  118. Kneidinger, 2008, The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils, Blood, 111, 3097, 10.1182/blood-2007-08-104372 · DOI
  119. Schade, 2008, Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation, Blood, 111, 1366, 10.1182/blood-2007-04-084814 · DOI
  120. Weichsel, 2008, Profound inhibition of antigen-specific T-cell effector functions by dasatinib, Clin Cancer Res, 14, 2484, 10.1158/1078-0432.CCR-07-4393 · DOI
  121. Sillaber, 2009, Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily, Eur J Clin Invest, 39, 1098, 10.1111/j.1365-2362.2009.02206.x · DOI
  122. Quintas-Cardama, 2007, Pleural effusion in patient with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure, J Clin Oncol, 25, 3908, 10.1200/JCO.2007.12.0329 · DOI
  123. Hochhaus, 2007, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, 109, 2303, 10.1182/blood-2006-09-047266 · DOI
  124. Rix, 2007, Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets, Blood, 110, 4055, 10.1182/blood-2007-07-102061 · DOI
  125. Deremer, 2011, Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia, Cancer Manag Res, 3, 65, 10.2147/CMAR.S11948 · DOI
  126. von Bubnoff, 2005, The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107, Leukemia, 19, 1670, 10.1038/sj.leu.2403887 · DOI
  127. Verstovsek, 2006, Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit, Leuk Res, 30, 1365, 10.1016/j.leukres.2006.04.005 · DOI
  128. Hochhaus, 2006, A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis, Blood, 108, 10.1182/blood.V108.11.2703.2703 · DOI
  129. Schenk, 1999, Signal preception and transduction: the role protein kinases, Biochim Biophys Acta, 1449, 1, 10.1016/S0167-4889(98)00178-5 · DOI
  130. Fishman, 1998, The role of protein kinase C in G1 and G2/M phases of the cell cycle (review), Int J Oncol, 12, 181
  131. Meyer, 1989, A derivative of staurosporine (CGP 41251) shows selectivity of protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int J Cancer, 43, 851, 10.1002/ijc.2910430519 · DOI
  132. Propper, 2001, Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J Clin Oncol, 19, 1485, 10.1200/JCO.2001.19.5.1485 · DOI
  133. Levis, 2006, Plasma inhibitory activity (PIA): a pharmacodynamid assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors, Blood, 108, 3477, 10.1182/blood-2006-04-015743 · DOI
  134. Gotlib, 2005, Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation, Blood, 106, 2865, 10.1182/blood-2005-04-1568 · DOI
  135. Krauth, 2009, Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells, Clin Exp Allergy, 39, 1711, 10.1111/j.1365-2222.2009.03353.x · DOI
  136. Gotlib, 2010, KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial, Blood, 116, 10.1182/blood.V116.21.316.316 · DOI
  137. Hahn, 2008, Masitinib is safe and effective for the treatment of canine mast cell tumors, J Vet Intern Med, 22, 1301, 10.1111/j.1939-1676.2008.0190.x · DOI
  138. Hahn, 2010, Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors, Am J Vet Res, 71, 1354, 10.2460/ajvr.71.11.1354 · DOI
  139. Corbin, 2004, Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970, Blood, 104, 3754, 10.1182/blood-2004-06-2189 · DOI
  140. Kosmider, 2007, Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate, Oncogene, 26, 3904, 10.1038/sj.onc.1210159 · DOI
  141. Pan, 2007, EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation, Blood, 109, 315, 10.1182/blood-2006-04-013805 · DOI
  142. Peter, 2010, KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406), Exp Hematol, 38, 782, 10.1016/j.exphem.2010.05.004 · DOI
  143. Corbin, 2005, In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit, Blood, 106, 227, 10.1182/blood-2004-12-4771 · DOI
  144. Faderl, 2009, Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells, Cancer Res, 69, 3910, 10.1158/0008-5472.CAN-08-0034 · DOI

Cited by

See all 102

Metadata

Authors
Ustun, C., DeRemer, D. L., & Akin, C.
Venue
Leukemia Research
Publisher
Elsevier BV
Published
2011-09
Volume
35
Issue
9
Pages
1143-1152
ISSN
0145-2126
DOI
10.1016/j.leukres.2011.05.006
Cited by
102
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. https://app.cochat.ai/papers/10.1016/j.leukres.2011.05.006
The paper
Ustun, C., DeRemer, D. L., & Akin, C. (2011). Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leukemia Research. https://doi.org/10.1016/j.leukres.2011.05.006